Antibody Activation and Immune Reactions: Potential Linkage to Pain and Neuropathy

Pain Medicine

Volumn 1, Issue 4, 2000, Pages 296-302

  Sorkin, Linda S ^a,b  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allodynia; Complement; Cytokines; Inflammation

Indexed keywords

EID: 0001433485     PISSN: 15262375     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4637.2000.00046.x     Document Type: Article

References (54)

1. Maves TJ, Gebhart GF, Meller ST. Continuous infusion of acidified saline around the rat sciatic nerve produces thermal hyperalgesia. Neurosci Lett 1995; 194:45-8.
2. Eliav E, Herzberg U, Ruda MA, Bennett GJ. Neuropathic pain from an experimental neuritis of the rat sciatic nerve. Pain 1999;83:169-82.
3. Hammock S, Milligan E, Gazda L, et al. Spinal interleukin-1 receptor antagonist blocks allodynia from zymosan-induced neuritis. Neurosci Abs 1999;25:1443.
4. Stoll G, Jung S, Jander S, van der Meide P, Hartung HP. Tumor necrosis factor-alpha in immune-mediated demyelination, Wallerian degeneration of the rat peripheral nervous system. J Neuroimmunol 1993;45:175-82.
5. Wagner R, Myers RR. Schwann cells produce tumor necrosis factor alpha: Expression in injured and non-injured nerves. Neurosci 1996;73:625-9.
6. Murwani R, Armati P. Peripheral nerve fibroblasts as a source of IL-6, TNFalpha and IL-1 and their modulation by IFN gamma. J Neurol Sci 1998;161:99-109.
7. Khalil Z, Liu T, Helme RD. Free radicals contribute to the reduction in peripheral vascular responses and the maintenance of thermal hyperalgesia in rats with chronic constriction injury. Pain 1999;79:31-7.
8. Redford EJ, Hall SM, Smith KJ. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain 1995;118:869-78.
9. Wagner R, Myers RR. Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuroreport 1996;7:2897-901.
10. Sorkin L, Doom C. Epineurial application of TNF elecits an acute mechanical hyperalgesia in the awake rat. J Peripher Nerv Syst 2000;5:96-1000.
11. Sorkin LS, Xiao WH, Wagner R, Myers RR. Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neurosci 1997; 81:255-62.
12. Leem J-G, Bove GM. The effect of neuritis and inflammatory substances on slowly conducting afferentfibers. Anesthesiol 2000;93 (suppl):A94.
13. Junger H, Sorkin LS. Nociceptive and inflammatory effects of subcutaneous TNF. Pain 2000;85:145-51.
14. Fukuoka H, Kawatani M, Hisamitsu T, Takeshige C. Cutaneous hyperalgesia induced by peripheral injection of interleukin 1-beta in the rat. Brain Res 1994;657:133-40.
15. Evans A, Junger H, Southall M, et al. Isoprostanes, novel eicosanoids that produce nociception and sensitize rat sensory neurons. J Pharmacol Exp Ther 2000;292:912-20.
16. Sommer C, Schmidt C, George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp Neurol 1998;151:138-42.
17. Kagan BL, Baldwin RL, Munoz D, Wisnieski BJ. Formation of ion-permeable channels by tumor necrosis factor-α. Science 1992;255:1427-30.
18. Baldwin RL, Stolowitz ML, Hood L, Wisnieski BJ. Structural changes of tumor necrosis factor alpha associated with membrane insertion and channel formation. Proc Natl Acad Sci USA 1996;93:1021-6.
19. Hribar M, Bloc A, van der Goot FG, et al. The lectin-like domain of tumor necrosis factor-alpha increases membrane conductance in microvascualr endothelial cells and peritoneal macrophages. Eur J Immunol 1999;29:3105-11.
20. Harvey GK, Gold R, Hartung HP, Toyka KV. Non-neural-specific T lymphocytes can orchestrate inflammatory peripheral neuropathy. Brain 1995;118: 1263-72.
21. Said G, Hontebeyrie-Joskowicz M. Nerve lesions induced by macrophage activation. Res Immunol 1992; 143:589-99.
22. Allen RR. Neuropathic pain in the cancer patient. Neurol Clin 1998;16:869-88.
23. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu - associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine 1992;71:59-72.
24. Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol 1992; 141:881-6.
25. Dalmau J, Furneaux HM, Gralla RJ, Kris MG, Posner JB. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer - a quantitative western blot analysis. Ann Neurol 1990;27: 544-52.
26. Graus F, Ribalta T, Campo E, et al. Immunohistochemical analysis of the immune reaction in the nervous system in paraneoplastic encephalomyelitis. Neurology 1990;40:219-22.
27. Posner JB. Anti-Hu autoantibody associated sensory neuropathy/encephalomyelitis: a model of paraneoplastic syndrome. Perspect Biol Med 1995;38: 167-81.
28. Furneaux HF, Reich L, Posner JB. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology 1990;40: 1085-91.
29. Oh SJ, Dropcho EJ, Claussen GC. Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature [see comments]. Muscle Nerve 1997;20:1576-82.
30. Quarles RH, Weiss MD. Autoantibodies associated with peripheral neuropathy. Muscle Nerve 1999;22: 800-22.
31. Hitoshi S, Kusunoki S, Murayama S, Tsuji S, Kanazawa I. Rabbit experimental sensory ataxic neuropathy: anti-GD1b antibody-mediated trkC down-regulation of dorsal root ganglia neurons. Neurosci Lett 1999;260:157-60.
32. Quarles RH. Glycoproteins of myelin sheaths. J Mol Neurosci 1997;8:1-12.
33. Hughes RA, Hadden RD, Gregson NA, Smith KJ. Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol 1999;100:74-97.
34. Moulin DE, Hagen N, Feasby TE, Amireh R, Hahn A. Pain in Guillain-Barré syndrome. Neurology 1997;48:328-31.
35. Moulin DE. Pain in central and peripheral demyelinating disorders. Neurol Clin 1998;16:889-98.
36. van der Meché FG, Meulstee J, Vermeulen M, Kievit A. Patterns of conduction failure in the Guillain-Barré syndrome. Brain 1988;111:405-16.
37. Prineas JW. Pathology of the Guillain-Barré syndrome. Ann Neurol 1981;9 (Suppl):6-19.
38. Bansil S, Mithen FA, Singhal BS, Cook SD, Rohowsky-Kochan C. Elevated neopterin levels in Guillain-Barré syndrome. Further evidence of immune activation. Arch Neurol 1992;49:1277-80.
39. Sharief MK, McLean B, Thompson EJ. Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome. Ann Neurol 1993;33:591-6.
40. George R, Spies J, Griffen JW. Immunology of the Peripheral Nervous System. In: Keane RW, Hickey WF, eds. Immunology of the Nervous System. New York: Oxford University Press; 1997:785-809.
41. Kaldor J, Speed BR. Guillain-Barré syndrome and Campylobacter jejuni: a serological study. BMJ 1984; 288:1867-70.
42. Illa I, Ortiz N, Gallard E, et al. Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol 1995;38:218-24.
43. Svennerholm L, Boström K, Fredman P, et al. Gangliosides and allied glycosphyngolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1994;1214:115-23.
44. Schultz G, Cheresh D, Varki N, et al. Detection of ganglioside GD2 in tumor tissues and sera neuroblastoma patients. Cancer Res 1984;44:5914-20.
45. Cheung NK, Saarinen UM, Neely JE, et al. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985;45:2642-9.
46. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998;16:2169-80.
47. Barker E, Mueller BM, Handgretinger R, et al. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991;51:144-9.
48. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 1992;3:19-24.
49. Kracun I, Rösner H, Cosovic C. Topographical distribution of the gangliosides in the developing and adult human brain. In: Kracun I, Rösner H, Cosovic C, eds. Fidia Research Series. Padova: Liviana Press; 1986:67-761.
50. Handgretinger R, Baader P, Dopfer R, et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14G2a. Cancer Immunol Immunother 1992;35:199-204.
51. Slart R, Yu AL, Yaksh TL, Sorkin LS. An animal model of pain produced by systemic administration of an immunotherapeutic anti-ganglioside antibody. Pain 1997;69:119-25.
52. Xiao WH, Yu AL, Sorkin LS. Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody. Pain 1997;69:145-51.
53. Gillin S, Sorkin LS. Gabapentin reverses the allodynia produced by the administration of anti-GD2 ganglioside, an immunotherapeutic drug. Anesth Analg 1998;86:111-6.
54. Wallace MS, Lee J, Sorkin L, et al. Intravenous lidocaine: effects on controlling pain after anti-GD2 antibody therapy in children with neuroblastoma - a report of a series. Anesth Analg 1997;85:794-6.